0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1391 Views 
0 Saved
0 Vote 1 Contributor1391 Views 0 SavedYou might also be interested in
You may find the hot flashes gradually decreasing with time after you start taking Arimidex; many women do. But we're talking years, not months, for them to vanish entirely. Some women even deal with hot flashes (usually much less intense and much less frequent) for the rest of their lives. Don't m....
Early signs of cancer could be unexplained weight loss, a lump or swelling, unusual bleeding, persistent fatigue or changes in skin. Some people also notice long-lasting coughs or changes in bowel habits. If you experience any of these symptoms, it is recommended to consult the best oncologist avail....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.